- Lexaria
Bioscience Corp. continues to make progress in the patenting and
development of its DehydraTECH™ platform
- Lexaria
developed the patented DehydraTECH™ drug delivery platform as a safer
alternative to inhalation of nicotine or cannabinoids
- DehydraTECH™
has been shown to facilitate rapid uptake and highly targeted delivery of
pharmaceuticals to the brain
Lexaria
Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has levered innovation,
research and development into operations in four market verticals: cannabis,
hemp, nicotine, and pharmaceuticals. Lexaria already introduced the
DehydraTECH™ drug delivery platform into commercial use and has a
second-generation delivery platform ready for launch in 2020. Lexaria is the
only company in the world to receive a patent for this improved oral delivery
of all non-psychoactive cannabinoids including CBD. In fact, the company has 16
patents already granted along with more than 60 patents that are pending
worldwide (http://ibn.fm/j08G0).
Lexaria has cannabinoid licensing agreements with various
companies in North America. The popularity of cannabinoid products such as CBD
is likely to increase in the future and the U.S. cannabis market alone is
projected to grow substantially in the future (http://ibn.fm/LsBtn). Lexaria’s
delivery technology is already being used by the CBD/hemp industry and could
experience radical growth in step with the industry.
The DehydraTECH™ drug delivery platform is an innovative
technology that was developed as a way to safely and effectively deliver
substances both to the bloodstream and to the brain via the oral ingestion route.
Substances such as nicotine and cannabidiol are historically inhaled, a choice
that is harmful to health compared with non-inhalation methods.
Inhalation can be problematic and dangerous especially for
individuals who may have other medical issues. The DehydraTECH™ drug delivery
platform can be used to deliver substances in edible or in beverage form, and
in capsules, pills, syrups and more. Brands in both Canada and the USA have
licensed DehydraTECH™ to make their CBD and cannabis beverages best-in-class.
Not only is ingestion a much safer form of drug delivery,
but DehydraTECH™ also delivers the active ingredient of the substance at a rate
that is up to five to ten times faster compared with traditional edible
products. A 2018 European clinical study demonstrated that 317 percent more CBD
was delivered within half an hour when compared with a positive control of
equal strength (http://ibn.fm/pXIxY).
The substance being delivered is also rapidly absorbed which means that people
can achieve the effect they are looking for more quickly than was previously
the case with edibles. For people looking for quick relief of pain, DehydraTECH
is a blessing.
Many human receptor cells are clustered primarily in the brain
or central nervous system, so in order to treat conditions, drugs need to
effectively reach these areas of the body which has historically been difficult
to do. Research studies done with animals have demonstrated delivery of 1,937
percent more cannabidiol (and over 500 percent more nicotine) into the brain
tissue after 8 hours when using the enhanced DehydraTECH™ when compared with
using generic industry MCT coconut-oil formulations. Greater effectiveness can
mean safer, lower doses. The increased bioavailability and speed of onset are
important factors when delivering substances to the brain and is especially
important for people who need rapid relief from unpleasant and debilitating
symptoms.
Studies done in the laboratory have also shown dramatically improved
oral nicotine delivery using the DehydraTECH™ platform. Lexaria has partnered
with one of the world’s largest tobacco companies to help fund the research and
development of DehydraTECH™ as it relates to nicotine delivery (http://ibn.fm/rlVJn).
A big advantage of the DehydraTECH™ drug delivery platform
when it comes to nicotine is that the delivery is fast when compared with other
oral forms of nicotine – such as nicotine lozenges or nicotine gum. Users are
less likely to get frustrated if they can feel the effects of the nicotine
faster when taken in through the oral route. Lower-risk technologies are needed
when it comes to nicotine, which is something that the government has
recognized since smoking is known to be deadly. Therefore, technology developed
to reduce health risks is highly beneficial.
DehydraTECH™ drug delivery platform has applications for the
pharmaceutical industry and could be used to deliver fat-soluble drugs. It also
could be used to deliver NSAID medications such as ibuprofen or acetylsalicylic
acid. DehydraTECH™ has the advantage of allowing substances to bypass first
phase liver metabolism.
The technology uses GRAS (Generally Recognized As
Safe) food ingredients and further advantages are that the technology
removes the bitter flavors and odors of many drugs. This is beneficial because
artificial sweeteners do not need to be added to the product to enhance its
taste and make it palatable. Sugar may be an issue, especially for people who
have diabetes, thus a sugar-free product would be a healthier option.
Lexaria was recently granted two granted patents related to
the treatment of heart disease, Alzheimer’s, Parkinson’s and schizophrenia. The
treatment of these and other types of neurological disorders in particular has
been problematic due to the blood-brain barrier – which makes it difficult for
the brain to take up the needed medications. This barrier is formed by
endothelial cells which function to prevent dangerous substances from passing
into the brain from blood vessels, but the problem is that this also often
stops helpful drugs from being able to enter the brain. The patented
DehydraTECH™ drug delivery platform helps overcome this limitation to rapidly
deliver essential medications to the brain.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment